Cartesian Therapeutics(RNAC) - 2025 Q2 - Quarterly Results

Cartesian Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update Initiated Phase 3 AURORA trial of Descartes-08 in myasthenia gravis Preliminary data from Phase 2 trial of Descartes-08 in systemic lupus erythematosus expected in 2H25 Exhibit 99.1 Initiation of Phase 2 pediatric basket trial of Descartes-08 in select autoimmune indications expected in 2H25 An encore presentation of the data, which were originally shared at the 2025 American Academy of Neurology Annual Meeting ...